| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Section of Urology, School of Medicine, Loma Linda University, Loma Linda 92354 [R. W. B., H. L. H., O. L. J.], and Department of Urology, White Memorial Medical Center, Los Angeles, California 90000 [A. L. D.]
Most low- and medium-stage (0, A, B1 and B2) and low-grade (I and II) tumors can be cured or controlled by adequate transurethral resection. This means wide and deep removal of the tumor, frequent follow-up examinations, and resection or electrocoagulation of recurrences. The 5-, 10-, 15-, and 20-year survivals of patients with low-stage and low-grade cancers compare favorably with the survival following more radical treatment (1, 3–7).
1 Presented at the National Bladder Cancer Conference, November 28 to December 1, 1976, Miami Beach, Fla.
2 Presenter. To whom requests for reprints should be addressed.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |